Sun Pharma Q2 net up 5% at Rs 2,375 crore
Sun Pharmaceutical Industries on Wednesday said its consolidated net profit increased by 5 per cent to Rs 2,375 crore for the second quarter ended September 30, driven by robust sales across domestic and US markets.
Sun Pharmaceutical Industries on Wednesday said its consolidated net profit increased by 5 per cent to Rs 2,375 crore for the second quarter ended September 30, driven by robust sales across domestic and US markets.
The drug major had reported a net profit of Rs 2,262 crore in the July-September period of last fiscal.
Total revenue from operations increased to 12,192 crore in the second quarter this fiscal, as compared to Rs 10,952 crore in the year-ago period, Sun Pharma said in a regulatory filing.
Sun Pharma Managing Director Dilip Shanghvi noted that the US FDA's acceptance of deuruxolitinib NDA for treatment of moderate to severe alopecia areata marked an important milestone for the company.
"There are limited treatment options for alopecia areata and deuruxolitinib should make a meaningful difference in patient lives, once approved," he added.
Similarly, another late stage candidate Nidlegy will potentially complement the company's Odomzo franchise, Shanghvi said.
The company said its formulation sales in the US stood at USD 430 million, recording a growth of 4.2 per cent over the second quarter of last fiscal.
The segment accounted for over 30 per cent of the company's total consolidated sales, it added.
Sales of formulations in India for the September quarter stood at Rs 3,842.5 million, up 11.1 per cent year-on-year, as compared to the same period last fiscal.
Domestic formulation sales accounted for about 32 per cent of the total consolidated sales, Sun Pharma said.
Shares of the company were trading 2.14 per cent up at Rs 1,111.95 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
Power of Compounding: How many years it will take to reach Rs 2 crore corpus if your monthly SIP is Rs 3,000, Rs 4,000, or Rs 5,000
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
02:34 PM IST